A citation-based method for searching scientific literature

Peter Hur, Nina Kim, Dong Dai, Olivia W Piao, Josh Z Zheng, Esther Yi. Drugs Real World Outcomes 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases.
Manon Belhassen, Florence Tubach, Christophe Hudry, Macha Woronoff-Lemsi, Laurie Levy-Bachelot, Eric Van Ganse, Bruno Fautrel. Br J Clin Pharmacol 2021
4
50

Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.
K Puolakka, H Kautiainen, M Pekurinen, T Möttönen, P Hannonen, M Korpela, M Hakala, M Arkela-Kautiainen, R Luukkainen, M Leirisalo-Repo. Ann Rheum Dis 2006
66
50

Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
Johan Dalén, Axel Svedbom, Christopher M Black, Ramon Lyu, Qian Ding, Shiva Sajjan, Vasilisa Sazonov, Sumesh Kachroo. Rheumatol Int 2016
44
50

Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Julie Vanderpoel, Joseph Tkacz, Brenna L Brady, Lorie Ellis. Clin Ther 2019
6
50

The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months.
Björn Wettermark, Niklas Hammar, Carl Michael Fored, Andrejs Leimanis, Petra Otterblad Olausson, Ulf Bergman, Ingemar Persson, Anders Sundström, Barbro Westerholm, Måns Rosén. Pharmacoepidemiol Drug Saf 2007
50


The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Ahva Shahabi, Jason Shafrin, Lauren Zhao, Sarah Green, Tammy Curtice, Alexander Marshall, Damemarie Paul. J Med Econ 2019
5
50

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.
J Braun, R van den Berg, X Baraliakos, H Boehm, R Burgos-Vargas, E Collantes-Estevez, H Dagfinrud, B Dijkmans, M Dougados, P Emery,[...]. Ann Rheum Dis 2011
626
50

Web Site and R Package for Computing E-values.
Maya B Mathur, Peng Ding, Corinne A Riddell, Tyler J VanderWeele. Epidemiology 2018
263
50


Sensitivity Analysis in Observational Research: Introducing the E-Value.
Tyler J VanderWeele, Peng Ding. Ann Intern Med 2017
50

Cost of biologic treatment persistence or switching in rheumatoid arthritis.
Tao Gu, Alex Mutebi, Bradley S Stolshek, Hiangkiat Tan. Am J Manag Care 2018
10
50




Economic Burden of Psoriasis and Potential Cost Offsets with Biologic Treatment: A Swedish Register Analysis.
Axel Svedbom, Johan Dahlén, Carla Mamolo, Joseph C Cappelleri, Lotus Mallbris, Ingemar F Petersson, Mona Ståhle. Acta Derm Venereol 2016
10
50

Medication compliance and persistence: terminology and definitions.
Joyce A Cramer, Anuja Roy, Anita Burrell, Carol J Fairchild, Mahesh J Fuldeore, Daniel A Ollendorf, Peter K Wong. Value Health 2008
50

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy.
Luca Degli Esposti, Ennio Giulio Favalli, Diego Sangiorgi, Roberta Di Turi, Giuseppina Farina, Marco Gambera, Roberto Ravasio. Clinicoecon Outcomes Res 2016
16
50

External review and validation of the Swedish national inpatient register.
Jonas F Ludvigsson, Eva Andersson, Anders Ekbom, Maria Feychting, Jeong-Lim Kim, Christina Reuterwall, Mona Heurgren, Petra Otterblad Olausson. BMC Public Health 2011
50

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
L Gossec, J S Smolen, C Gaujoux-Viala, Z Ash, H Marzo-Ortega, D van der Heijde, O FitzGerald, D Aletaha, P Balint, D Boumpas,[...]. Ann Rheum Dis 2012
339
50

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs.
Rosarin Sruamsiri, Hideto Kameda, Jörg Mahlich. Drugs Real World Outcomes 2018
13
50



The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data.
A Desgagné, A M Castilloux, J F Angers, J LeLorier. Pharmacoeconomics 1998
125
50


Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
Grant W Cannon, Scott L DuVall, Candace L Haroldsen, Liron Caplan, Jeffrey R Curtis, Kaleb Michaud, Ted R Mikuls, Andreas Reimold, David H Collier, George J Joseph,[...]. Adv Ther 2016
12
50

The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany.
Kathrin Ziegelbauer, Karel Kostev, Maximilian Hübinger, Silvia Dombrowski, Michael Friedrichs, Heiko Friedel, Sumesh Kachroo. Rheumatology (Oxford) 2018
5
50


Sick leave patterns in common musculoskeletal disorders--a study of doctor prescribed sick leave.
Jenny Hubertsson, Martin Englund, Ulf Hallgårde, Ulrik Lidwall, Sofia Löfvendahl, Ingemar F Petersson. BMC Musculoskelet Disord 2014
38
50


Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Jessica A Walsh, Oluwakayode Adejoro, Benjamin Chastek, Jacqueline B Palmer, Peter Hur. J Manag Care Spec Pharm 2018
21
50


Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.
Andrew Blauvelt, Nianwen Shi, Russel Burge, William N Malatestinic, Chen-Yen Lin, Carolyn R Lew, Nicole M Zimmerman, Orin M Goldblum, Baojin Zhu, Mwangi J Murage. Patient Prefer Adherence 2020
18
50

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.
Huabin F Zhang, Geneviève Gauthier, Robert Hiscock, Jeffrey R Curtis. Arthritis Res Ther 2014
19
50

Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Steven R Feldman, Corey L Pelletier, Kathleen L Wilson, Rina K Mehta, Matthew A Brouillette, David Smith, Machaon M Bonafede. J Comp Eff Res 2019
6
50

Economic Burden of Psoriasis in the United States: A Systematic Review.
Elizabeth A Brezinski, Jaskaran S Dhillon, April W Armstrong. JAMA Dermatol 2015
141
50

Treatment guidelines in psoriatic arthritis.
Alexis Ogdie, Laura C Coates, Dafna D Gladman. Rheumatology (Oxford) 2020
55
50

Obesity in psoriatic arthritis: Comparative prevalence and associated factors.
Rubén Queiro, Andrés Lorenzo, Patricia Tejón, Pablo Coto, Estefanía Pardo. Medicine (Baltimore) 2019
28
50

Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
Andrew Blauvelt, Nianwen Shi, Russel Burge, William N Malatestinic, Chen-Yen Lin, Carolyn R Lew, Nicole M Zimmerman, Orin M Goldblum, Baojin Zhu, Mwangi J Murage. J Am Acad Dermatol 2020
29
50

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Care Res (Hoboken) 2019
130
50

Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database.
Kurt R Oelke, Olivier Chambenoit, Amar Q Majjhoo, Stephani Gray, Kate Higgins, Peter Hur. J Comp Eff Res 2019
25
50

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
A Blauvelt, K A Papp, H Sofen, M Augustin, G Yosipovitch, N Katoh, U Mrowietz, M Ohtsuki, Y Poulin, D Shrom,[...]. J Eur Acad Dermatol Venereol 2017
42
50

Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
Jalpa A Doshi, Junko Takeshita, Lionel Pinto, Penxiang Li, Xinyan Yu, Preethi Rao, Hema N Viswanathan, Joel M Gelfand. J Am Acad Dermatol 2016
70
50

The Epidemiology of Psoriatic Arthritis.
Alexis Ogdie, Pamela Weiss. Rheum Dis Clin North Am 2015
229
50


Psoriatic Arthritis: What is Happening at the Joint?
Jennifer Belasco, Nathan Wei. Rheumatol Ther 2019
25
50



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.